Baragetti, Andrea Bonacina, Fabrizia Da Dalt, Lorenzo Moregola, Annalisa Zampoleri, Veronica Pellegatta, Fabio Grigore, Liliana Pirillo, Angela Spina, Rossella Cefalù, Angelo Baldassarre
...
Published in
European journal of preventive cardiology
Leucocyte telomere length (LTL) shortening is a marker of cellular senescence and associates with increased risk of cardiovascular disease (CVD). A number of cardiovascular risk factors affect LTL, but the correlation between elevated LDL cholesterol (LDL-C) and shorter LTL is debated: in small cohorts including subjects with a clinical diagnosis o...
Pérez de Isla, Leopoldo Watts, Gerald F Muñiz-Grijalvo, Ovidio Díaz-Díaz, Jose Luis Alonso, Rodrigo Zambón, Daniel Fuentes-Jimenez, Francisco Mauri, Marta Padró, Teresa Vidal-Pardo, José I
...
Published in
European journal of preventive cardiology
Knowledge of the features of patients with familial hypercholesterolaemia (FH) who are protected from atherosclerotic cardiovascular disease (ASCVD) is important for the clinical and prognostic care of this apparently high-risk condition. Our aim was to investigate the determinant and characteristics of patients with FH who are protected from ASCVD...
Gaudet, Daniel López-Sendón, José Luis Averna, Maurizio Bigot, Grégory Banach, Maciej Letierce, Alexia Loy, Megan Samuel, Rita Manvelian, Garen Batsu, Isabela
...
Published in
European journal of preventive cardiology
To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardiovascular (CV) risk patients with heterozygous familial hypercholesterolaemia (HeFH) or very-high low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated dose of statin ± other lipid...
Liu, Ming-Ming Peng, Jia Guo, Yuan-Lin Wu, Na-Qiong Zhu, Cheng-Gang Gao, Ying Dong, Qian Li, Jian-Jun
Published in
European journal of preventive cardiology
Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular disease. However, the association between T2DM and coronary artery disease (CAD) in patients with heterozygous familial hypercholesterolaemia (HeFH) has not been thoroughly evaluated. Our study aimed to assess the effect of T2DM on CAD severity and hard cardiovascular ...
Hauguel-Moreau, Marie Aïdan, Vincent Hergault, Hélène Beauchet, Alain Pépin, Marion Prati, Giulio Pillière, Rémy Ouadahi, Mounir Josseran, Loïc Rodon, Christophe
...
Background: Familial hypercholesterolaemia (FH) is responsible for severe hypercholesterolaemia and premature cardiovascular morbidity and mortality. The first clinical event is typically an acute coronary syndrome. Unfortunately, FH is largely underdiagnosed in the general population. Aims: To assess the prevalence of clinical FH among patients wi...
Marquina, Clara Lacaze, Paul Tiller, Jane Riaz, Moeen Sturm, Amy C Nelson, Mark R Ference, Brian A Pang, Jing Watts, Gerald F Nicholls, Stephen J
...
Published in
European heart journal
The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH). We designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cho...
Chua, Yung-An Razman, Aimi Zafira Ramli, Anis Safura Mohd Kasim, Noor Alicezah Nawawi, Hapizah
Published in
Journal of atherosclerosis and thrombosis
Familial hypercholesterolaemia (FH) is the most common autosomal dominant lipid disorder, leading to severe hypercholesterolaemia. Early detection and treatment with lipid-lowering medications may reduce the risk of premature coronary artery disease in FH patients. However, there is scarcity of data on FH prevalence, detection rate, treatment and c...
Susekov, Andrey V Korol, Ludmila A Watts, Gerald F
Published in
Cardiovascular drugs and therapy
An elevated plasma low-density lipoprotein cholesterol (LDL-C) level is a well-established atherosclerotic cardiovascular disease (ACSVD) risk factor. Randomized studies with statins (alone or in combination with other lipid-lowering drugs) have demonstrated their clinical efficacy in lowering LDL-C. Several classes of new, non-statin agents have b...
Watts, Gerald F Sullivan, David R Hare, David L Kostner, Karam M Horton, Ari E Bell, Damon A Brett, Tom Trent, Ronald J Poplawski, Nicola K Martin, Andrew C
...
Published in
American journal of preventive cardiology
Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease, with significant potential for positive impact on public health and healthcare savings. New clinical practice recommendations are presented in an abridged guidance to assist practitioners in enhancing the care of all patients with ...
Descamps, Olivier S Rietzschel, Ernst Laporte, Anja Buysschaert, Ian De Raedt, Herbert Elegeert, Ivan Chenot, Fabien Lengele, Jean-Philippe Carlier, Stephane Vanderheeren, Philippe
...
Published in
Acta cardiologica
Familial hypercholesterolaemia (FH) is underdiagnosed in most countries. We report our first experience from a national pilot project of cascade screening in relatives of FH patients. Participating specialists recruited consecutive index patients (IP) with Dutch Lipid Clinic Network (DLCN) score ≥6. After informed consent, the relatives were visite...
